Global Respiratory Drug Delivery Technologies market is projected to grow at a CAGR of 7.31% by 2032: Visiongain Reports Ltd – Yahoo Finance
Visiongain has published a new report: Global Respiratory Drug Delivery Technologies Market, (COVID-19 Impact Analysis):- Market Segment by Product (Formulations and Devices), by Type (Dry Powder, Suspension Aerosol, and Solution Aerosol), by Product Type (Metered Dose Inhalers (MDIS), Dry Powder Inhalers (DPIs), Nebulizers and Accessories), by Nebulizers Type (Soft Mist Nebulizers, Jet Nebulizers and Ultrasonic Nebulizers), by Canister Type (Plain Canisters and Coated Canister), by Application (Asthma. COPD, Cystic Fibrosis and Others) and End User (Homecare, Hospitals & Clinics and Others) PLUS COVID-19 Impact Analysis and Recovery Pattern Analysis (“V”-shaped, “W”-shaped, “U”-shaped, “L”-shaped) Profiles of Leading Companies, Region and Country.
The global respiratory drug delivery technologies market was valued at US$59.51 billion in 2022 and is projected to grow at a CAGR of 7.31% during the forecast period 2022-2032.
Increasing prevalence and incidence of respiratory diseases
Prevalence and incidence of respiratory diseases are increasing worldwide because of various factors including pollution, unhealthy lifestyle, and tobacco smoking. According to the Global Burden of Diseases Study (2017), there were approximately 3.2 million deaths due to COPD (Chronic Obstructive Pulmonary Disease and 495,000 due to asthma. COPD accounts to be the seventh leading cause of life loss due to premature deaths. There has been a rise in demand and the adoption of respiratory drugs is advancing owing to novel product launches, faster absorption, suitable toxicology framework, and patient adherence. The advanced drugs require advanced delivery systems to make the treatment effective. These factors paved the way for innovative respiratory drug delivery technologies that are less invasive, localized, and have the capabilities to effectively administer the drug in the respiratory system within a shorter time span.
Download Exclusive Sample of Report @
https://www.visiongain.com/report/respiratory-drug-delivery-market-2022/#download_sampe_div
How has COVID-19 had a significant positive impact on the Respiratory Drug Delivery Technologies Market?
The COVID-19 epidemic has considerably speeded the adoption of novel & portable respiratory drug delivery technologies, with a preference for completely remote home-care settings. Due to the outbreak of COVID-19, the significant demand for respiratory drugs and devices led to a shortfall in supply in many countries. Many patient deaths were reported due to lack of respiratory drugs and devices. The patients were compelled to stay home and arrange resources themselves, thereby boosting the purchase of respiratory drugs and delivery devices such as nebulizers, inhalers, and other portable devices.
How this Report will benefit you?
Visiongain’s 595 page report provides 454 tables and 454 charts/graphs. Our new study is suitable for anyone requiring commercial, in-depth analyses for the global respiratory drug delivery technologies market, along with a detailed segment analysis in the market. Our new study will help you evaluate the overall global and regional market for Respiratory Drug Delivery Technologies. Get the financial analysis of the overall market and different segments and, company size. We believe that there are strong opportunities in this fast-growing respiratory drug delivery technologies market. See how to use the existing and upcoming opportunities in this market to gain revenue benefits in the near future. Moreover, the report will help you to improve your strategic decision-making, allowing you to frame growth strategies, reinforce the analysis of other market players and, maximise the productivity of the company.
What are the Current Market Drivers?
Outbreak of COVID-19 Pandemic
The uncertainty surrounding coronavirus illness 2019 (COVID-19) prompted anticipatory purchases of respiratory drugs all around the world, boosting demand to an all-time high. Meanwhile, drug companies were shut down to limit the spread of COVID-19, disrupting the drug supply chain and resulting in drug shortages. In response to these prescription drug shortages, pharmacy workers implemented local policy modifications, thorough antimicrobial stewardship, and quantity limitations for in-demand drugs.
For instance, Because of the specific lung tissues affected by the virus, COVID-19 therapy frequently includes the use of bronchodilators. Given that nebulizers promote the formation of aerosolized virus in COVID-19 patients, potentially exacerbating the virus’s dissemination, MDI usage is preferable. Inhaler shortages were on rise as a result of increased medical demand for COVID-19 treatment. This shows that since the COVID-19 pandemic, the demand for respiratory drug delivery technologies has increased for the treatment of patients suffering with COVID-19, asthma, bronchitis, and other respiratory diseases.
Growing Support of Government and NGOs for Respiratory Diseases Healthcare Awareness
Growing awareness coupled with government support about respiratory diseases is another major driver that propels the market growth. The increase in the number of respiratory diseases incidence has involved governments around the world taking necessary action to address this condition. A range of programs and initiatives aimed at supporting the treatment and management of asthma, COPD, and other chronic respiratory conditions address chronic respiratory conditions at the national level. Significant funding is also provided to ensure quality clinical research on chronic respiratory conditions is conducted and national monitoring and monitoring measures are maintained. Some of the recent developments in this regard are as mentioned below:
In March 2019, the WHO Global TB Program developed a new digital platform for country implementation to store, analyse and visualize national and subnational TB surveillance data. The platform will facilitate programmatic action and timely planning.
The Respiratory Health Program (RHP) provides national and international leadership to prevent work-related respiratory diseases and optimize the respiratory health of workers by generating new knowledge and transferring that knowledge to the benefit of workers in practice. The RHP specializes in the identification, evaluation and prevention of respiratory diseases related to the workplace and provides resources, products, and services to those in need and those capable of prevention.
The Australian Government has supported the National Asthma Council to develop the National Asthma Strategy 2018 (the Strategy) in partnership with Asthma Australia. The strategy, launched by the Minister of Health Hon Greg Hunt MP on 31 January 2018, draws on best-practice understandings of optimal care and management of asthma and incorporates advice from clinical and academic experts. In line with the National Strategic Framework for Chronic Conditions and the National Aboriginal and Torres Strait Islander Health Plan Implementation Plan 2013-2023, the Strategy outlines a targeted and comprehensive approach to optimizing asthma diagnosis and management.
Where are the Market Opportunities?
Particle Engineering and Metered Dose Inhaler (MDI) Technology to propel the Market Growth
There has been a lot of interest gathered regarding particle engineering which makes use of nanoparticles and nanocrystals as the primary formulation for respiratory drug delivery. For effective pulmonary drug delivery, both device and formulation are critical. Commercially available particle technology includes Pulmospheres (Novartis), Aerospheres (AstraZeneca), Technospheres (Mannkind Corporation), Arcus (Acroda Therapeutics), and PRINT (Liquidia Corporation). Although dry powder inhalers are gaining a slow hold, pMDI still continues to grab the market share owing to its popularity based on the number of doses and number of units sold. The Autohaler (3M) was the first dose metered inhaler to be actuated by breath or activated by pressure. Autohaler solved the major concern of the pressure metered-dose inhaler (pMDI) and did not rely on the patient’s inhalation effort to aerosolize the dry powder inhaler dose. Moreover, electronic inhalers are gradually making their presence in the market to meet the demand for patient adherence and compliance. In January 2020, Aptar Pharma and Lupin Ltd. launched ADHERO, a reusable, bluetooth-enabled smart device that can be attached to the top of an MDI. Also, in December 2020, Kindeva Drug Delivery and Breath of Life International signed an agreement to research the feasibility of numerous inhaled cannabinoid drugs. According to the agreement, Kindeva will develop new formulations of Breath of Life Pharma’s cannabinoid-based drugs delivered by Kindeva’s MDI technology. Thus, such developments in the market are expected to drive market growth.
Competitive Landscape
The major players operating in the respiratory drug delivery technologies market are AptarGroup, Inc., AstraZeneca plc., Boehringer Ingelheim GmbH, Cipla Limited, Graham Field Health Products, GSK Corporation, Medisana GmbH., Merck & Co., Inc., Novartis AG, Omron Corporation, Philips Respironics, Recipharm Ab., Sunovion Pharmaceuticals Inc. Teva Pharmaceuticals and 3M Healthcare. These major players operating in this market have adopted various strategies comprising M&A, investment in R&D, collaborations, partnerships, regional business expansion, and new product launches
Recent Developments
Novartis’s Sandoz announced to have acquired respiratory device and drug development company Coalesce in 2022.
AstraZeneca and Honeywell signed exclusive partnership agreement to develop new inhalers based on HFO-1234ze technology
AstraZeneca has completed the transfer of its global rights to Eklira (aclidinium bromide), known as Tudorza in the US, and Duaklir (aclidinium bromide/formoterol), ( inhaled respiratory medicines) to Covis Pharma Group (Covis Pharma)
Avoid missing out by staying informed – order our report now.
Find more Visiongain research reports on Pharma sector click on the following links:
Vaccine Sales Market Report 2022-2032
Veterinary Vaccines Market Report 2022-2032
Meningococcal Vaccines Market Report 2021-2031
Anti-infective Vaccines Market Report 2021-2031
Do you have any custom requirements we can help you with? Any need for a specific country, geo region, market segment or specific company information? Contact us today, we can discuss your needs and see how we can help: dev.visavadia@visiongain.com
About Visiongain
Visiongain is one of the fastest-growing and most innovative independent market intelligence around, the company publishes hundreds of market research reports which it adds to its extensive portfolio each year. These reports offer in-depth analysis across 18 industries worldwide. The reports cover a 10 year forecasts, are hundreds of pages long, with in depth market analysis and valuable competitive intelligence data. Visiongain works across a range of vertical markets, which currently can influence one another, these markets include automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors. Our customized and syndicated market research reports means that you can have a bespoke piece of market intelligence customized to your very own business needs.
Contact:
Dev Visavadia
PR at Visiongain Reports Limited
Tel: + 44 0207 336 6100
Email: dev.visavadia@visiongain.com
Gilead announced Monday that the overall survival rate for patients taking the drug had achieved statistical significance.
Lilly (LLY) expects to launch five new medicines by 2023 end including Mounjaro for type II diabetes (already launched) and donanemab for early Alzheimer's disease.
Viridian unveiled promising results Monday for its Horizon-rivaling thyroid eye disease treatment — and the biotech stocks diverged.
Plus Therapeutics Inc (NASDAQ: PSTV) presented data from two ongoing trials of its lead investigational drug, Rhenium-186 Nanoliposome (186RNL), for recurrent glioblastoma (GBM) and leptomeningeal metastases. The data from LM patients demonstrated that the 186RNL dose administered through an intraventricular catheter at 6.6 mCi in 5.0 mL achieved absorbed doses of 18.7 to 29.0 Gy, which were well tolerated with mild treatment-related adverse events. Furthermore, all three patients in the cohort
Shares of Gilead Sciences Inc. were up 4.9% in trading on Monday after the company said in a news release that Trodelvy improved overall survival rates in people with HR+/HER2- metastatic breast cancer. Gilead said it already filed an application with the Food and Drug Administration asking the regulator to approve the Trodelvy for this group of patients. It also said it expects to soon share full data from this clinical trial, which will help Wall Street analysts understand how Trodelvy will co
By John Vandermosten, CFA NASDAQ:ACHV READ THE FULL ACHV RESEARCH REPORT Second Quarter 2022 Results Achieve Life Sciences, Inc. (NASDAQ:ACHV) reported second quarter 2022 results in a press release and held a conference call after market close on August 11, 2022. The company concurrently filed its Form 10-Q with the SEC. Since its first quarter update, Achieve has begun its long-awaited vaping
The Internal Revenue Service has proposed rule changes that could significantly impact how beneficiaries will manage inherited retirement accounts. The proposed regulations, which were published last month, caught some in the financial services industry by surprise, as they offer a … Continue reading → The post The IRS May Make Your Roth IRA More Valuable With This RMD Rule Change appeared first on SmartAsset Blog.
Is Pfizer stock a buy after the company announced its $5.4 billion plan to buy Global Blood Therapeutics? Is PFE stock a buy right now?
Currently, Novavax (NVAX) has only one marketed product in its portfolio, its protein-based COVID-19 vaccine. However, it is lagging in competition behind mRNA-based vaccines.
Immunovant (IMVT) remains focused on developing its lead pipeline candidate, batoclimab for treating several types of autoimmune diseases. The lack of other pipeline candidates remains a concern.
Why are eggs so expensive now? The average price of a dozen large, Grade A eggs was $2.94 in July, up 38% from the same period last year at $1.64, according to the U.S. Bureau of Labor Statistics. The price of eggs has been trending upward since the beginning of 2022, and egg experts said an avian influenza outbreak that has severely limited the supply of eggs was the leading cause of high prices.
(Reuters) -Saudi Arabia's Kingdom Holding Co, the investment firm controlled by billionaire Prince Alwaleed Bin Talal, quietly invested more than $500 million in three major Russian energy companies between February and March, regulatory filings showed. By investing in Gazprom, Rosneft and Lukoil, Kingdom was likely seeking undervalued assets, but its move came as many Western nations imposed sanctions on Russian energy firms and their executives following Russia's invasion of Ukraine on Feb. 24.
A federal judge in California has signed off on Apple Inc.'s $30.5 million settlement in a nearly decade-old lawsuit claiming the company shortchanged 15,000 retail workers by not paying them for time spent in security checks after their shifts. U.S. District Judge William Alsup in San Francisco approved the settlement in the 2013 class action on Saturday. The California Supreme Court in 2020 used the case to rule that state law requires employees to be paid when they go through mandatory security screenings.
Yahoo Finance Live host Seana Smith peeks at Warner Bros. Discovery stock following reported job cuts and the production companies' transition into its merger.
Since then, Congress announced it is making changes to the $7,500 federal electric vehicle tax credit, meaning that it becomes much harder to get that sweet, sweet tax deduction. The two major changes are that the tax credit will becomes means-tested (i.e., if your household makes more than a certain amount, you don't qualify) and sticker-price limited (cars over $40,000 and SUVs and trucks with a slightly higher limit). Various car manufacturers have scrambled to figure out how to react, but VinFast is taking more extreme steps than most, promising that if you have a preorder with the manufacturer and you are no longer eligible for the tax rebate, they'll give you a $7,500 discount on the car instead.
Knowing how much you need for retirement is multi-factored: It’s not just about how much you saved, it’s also about knowing how much you will spend on a monthly basis. “Typically, people need around 70% to 80% of the pre-retirement income in retirement to maintain a lifestyle,” says certified financial planner Spencer Betts of Bickling Financial Services.
McDonald’s has kicked off a recruitment drive to hire more over-50s, amid a scramble by businesses across the country to fill jobs with retirees.
How much difference would $200,000 make to your retirement nest egg? If you decide you can retire comfortably with $200,000 less in savings, how much sooner could you retire? Now, 401(k) members say they'll need only $1.7 million for retirement.
AstraZeneca is the IBD Stock Of The Day amid growing enthusiasm for its cancer drug, Enhertu. But AZN stock hit resistance Monday.
Sound Planning Group CEO David Stryzewski and Robert Cantwell, Upholdings Founder & Portfolio Manager, join Yahoo Finance Live to discuss the market outlook, forecast for retailers, and the Fed's interest rate hike cycle.